Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
NT$ 67.2
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatment of cancer and...
Company Valuation
Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers.
Data is available to registered users only
Buy
Sell